23 completed. 23 Phase 3, 3 Phase 2.
By phase and status
Follow Meningococcal Disease: new trials by email Literature Review of Meningococcal Disease trials Research Report on Meningococcal Disease
Trials (filtered) newest first · largest first
All 23 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan. Bexsero®, Routine vaccines - Meningococcal Disease, Infections, Meningococcal Phase 3 Completed 225 2014-09-11 2020-08-25
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. rMenB+OMV - Meningococcal Disease Phase 3 Completed 239 2014-05-01 2017-02-15
Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. Meningococcal B Recombinant vaccine rMenB+OMV NZ, Placebo, Meningococcal ACWY-CRM conjugate vaccine - Meningococcal Disease Phase 3 Completed 264 2013-11-01 2015-10-30
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Recombinant meningococcal B + OMV NZ - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 18 2013-05-01 2015-03-27
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 805 2012-11-01 2015-01-13
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia MenACWY-CRM - Meningococcal Disease Phase 3 Completed 198 2012-11-01 2023-04-28
Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. MenACWY-CRM - Meningococcal Disease, Infections, Meningococcal Phase 3 Completed 715 2012-10-07 2019-06-14
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Disease Phase 3 Completed 300 2012-07-01 2013-12-03
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 552 2011-11-01 2014-03-11
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 252 2011-10-01 2017-06-08
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Serogroup B meningococcal vaccine - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 344 2011-08-01 2015-02-20
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine MenACWY-CRM - Meningococcal Disease Phase 3 Completed 205 2011-05-01 2018-06-18
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years rMenB + OMV NZ vaccine, Meningococcal C oligosaccharide conjugated vaccine, Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 1409 2011-04-01 2016-05-09
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Novartis MenACWY-CRM, Saline Placebo - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 450 2010-12-01 2012-10-16
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life MenACWY-CRM, Routine Vaccines - Meningococcal Disease, Meningococcal Meningitis Phase 3 Completed 751 2010-10-01 2018-10-09
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis Phase 2 / Phase 3 Completed 817 2010-08-01 2018-06-15
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age rMenB+OMV NZ - Meningococcal Disease Phase 3 Completed 508 2010-06-01 2015-04-10
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months MenACWY-CRM, DTaP-IPV/Hib, HBV - Meningococcal Disease Phase 3 Completed 529 2009-11-01 2014-04-21
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 rMenB+OMV NZ with routine vaccinations, rMenB+OMV NZ, two doses of rMenB+OMV NZ - Meningococcal Disease, Meningococcal Meningitis Phase 2 / Phase 3 Completed 1588 2009-07-01 2017-08-14
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers 1a - rMenB+OMV NZ and routine vaccines, 1b - rMenB+OMV NZ and routine vaccines, 2a - Routine and rMenB+OMV NZ vaccines - Meningococcal Disease Phase 3 Completed 2249 2009-02-01 2015-03-03
Showing 20 of 23. Sign in to see all of them.
Narrower conditions Meningococcal Infections (23) · Meningitis (11) · Meningitis, Meningococcal (11) · Encephalitis, Japanese (1) · Hepatitis A (1) · Hepatitis B (1) · Hereditary Complement Deficiency Diseases (1) · Rabies (1) · Typhoid Fever (1) · Yellow Fever (1)
Broader conditions Bacterial Infections (23) · Bacterial Infections and Mycoses (23) · Gram-Negative Bacterial Infections (23) · Infections (23) · Neisseriaceae Infections (23) · Nervous System Diseases (18) · Neuroinflammatory Diseases (18) · Central Nervous System Bacterial Infections (11) · Central Nervous System Diseases (11) · Central Nervous System Infections (11) · Meningitis, Bacterial (11) · Meningitis (7) · RNA Virus Infections (2) · Virus Diseases (2) · Arbovirus Infections (1)
Interventions MenACWY-CRM vaccine (7) · 4CMenB vaccine (3) · Hepatitis B Vaccines (2) · Tetanus Toxoid (2) · 13-valent pneumococcal vaccine (1) · Engerix-B (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Japanese Encephalitis Vaccines (1) · Measles-Mumps-Rubella Vaccine (1) · Meningococcal Vaccines (1) · Rabies Vaccines (1) · Rubella Vaccine (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1) · adacel (1)
Sponsors Novartis Vaccines (17) · Novartis (3) · GlaxoSmithKline (2) · Sanofi Pasteur, a Sanofi Company (1)
Countries Italy (6) · Czechia (5) · Germany (5) · Spain (4) · Canada (3) · South Korea (3) · United Kingdom (3) · United States (3) · Australia (2) · Chile (2) · Finland (2) · Russia (2) · Argentina (1) · Austria (1) · Belgium (1)
Results publications PMID 33020485 , PMID 19895922 , PMID 20164251 , PMID 22260988 , PMID 23324563 , PMID 24873986 , PMID 25308927 , PMID 25483566 , PMID 26232542 , PMID 26398741 , PMID 26479973 , PMID 26756390 , PMID 26826544 , PMID 28318767 , PMID 29038320 , PMID 29253560 , PMID 30068713 , PMID 31110098 , PMID 31327652 , PMID 33325757
NIH funding 2005 (1) , 2008 (1) , 2009 (1) , 2014 (1)